Immunomodulation Following Chemotherapy

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1996 Jan 1

PMID 8825121

Citations 1

Authors

M Obadina

U Verma

M Hawkins

A Mazumder

Affiliations

Soon will be listed here.

Abstract

In the last decade, immunomodulation has emerged as a mode of therapy capable of mediating the regression of cancer in some patients. This article reviews our experience with immunomodulation following transplant and non-transplant chemotherapy. We used interferon and cyclosporine A following conventional chemotherapy in a non-transplant setting for a B16 melanoma in a murine model. This combination generated cells with MHC-unrestricted cytotoxicity. We have also used immunotherapy in the transplant setting with IL-2 activated PBSC in patients with breast cancer. Of the 28 patients treated, 20 developed GVHD and the average time to reconstitution was 12 days (comparable to a control group). This article also raises the possibility of extending immunomodulation to breast cancer patients in the nontransplant setting to induce an antitumor immune response following cytoreductive chemotherapy.

Citing Articles

Use of tumor lines with selectable markers in assessing the effect on experimental metastases of combination chemotherapy with alkylating agents.

Miller B, Delmonico L, Vistisen K, Miller F Clin Exp Metastasis. 1999; 16(5):480-8.

PMID: 10091943 DOI: 10.1023/a:1006541710377.

References

Charak B, Agah R, Mazumder A . Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood. 1993; 81(12):3474-9. View

Verma U, Areman E, Dickerson S, Kotula P, Sacher R, Mazumder A . Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant. 1995; 15(2):199-206. View

Charak B, Sadowski R, Mazumder A . Antitumor effect of interferon plus cyclosporine A following chemotherapy for disseminated melanoma. Cancer Res. 1992; 52(23):6482-6. View

Lotze M, Custer M, Sharrow S, Rubin L, Nelson D, Rosenberg S . In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 1987; 47(8):2188-95. View

Rosenberg S . Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today. 1988; 9(2):58-62. DOI: 10.1016/0167-5699(88)91261-3. View

Soiffer R, Murray C, Cochran K, Cameron C, Wang E, Schow P . Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992; 79(2):517-26. View

Waldmann T . The multi-subunit interleukin-2 receptor. Annu Rev Biochem. 1989; 58:875-911. DOI: 10.1146/annurev.bi.58.070189.004303. View

Ujiie T . Increased sensitivity of tumor cells to immune defense cells following treatment with antineoplastic agents in vitro. Jpn J Exp Med. 1989; 59(1):17-26. View

Rosenberg S, Grimm E, McGrogan M, Doyle M, Kawasaki E, Koths K . Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984; 223(4643):1412-4. DOI: 10.1126/science.6367046. View

10.

Nagarkatti M, Kaplan A . The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor. J Immunol. 1985; 135(2):1510-7. View

11.

NORTH R . Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982; 155(4):1063-74. PMC: 2186638. DOI: 10.1084/jem.155.4.1063. View

12.

Khayat D, Borel C, Tourani J, Benhammouda A, Antoine E, Rixe O . Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993; 11(11):2173-80. DOI: 10.1200/JCO.1993.11.11.2173. View

13.

Richards J, Mehta N, Ramming K, Skosey P . Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992; 10(8):1338-43. DOI: 10.1200/JCO.1992.10.8.1338. View

14.

Hamon M, Prentice H, Gottlieb D, Macdonald I, Cunningham J, Smith O . Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant. 1993; 11(5):399-401. View

15.

Kennedy M, Vogelsang G, Beveridge R, Farmer E, Altomonte V, Huelskamp A . Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol. 1993; 11(3):478-84. DOI: 10.1200/JCO.1993.11.3.478. View

16.

Rosenberg S, Lotze M, Yang J, Linehan W, Seipp C, Calabro S . Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989; 7(12):1863-74. DOI: 10.1200/JCO.1989.7.12.1863. View

17.

Charak B, Brynes R, Katsuda S, Groshen S, Chen S, Mazumder A . Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy. Cancer Res. 1991; 51(8):2015-20. View

18.

Gastl G, Marth C, Leiter E, Gattringer C, Mayer I, Daxenbichler G . Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res. 1985; 45(7):2957-61. View

19.

Klingemann H, Grigg A, Barnett M, Eaves A, Reece D, Shepherd J . Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood. 1991; 78(12):3306-11. View

20.

Verma U, Bagg A, Brown E, Mazumder A . Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant. 1994; 13(2):115-23. View